[1] In terms of its molecular structure, it is related anthraquinone by the replacement of two hydrogen atoms by hydroxyl groups (–OH).

It should not be confused with ondansetron, an unrelated drug that was marketed in South Africa under the trade name "Dantron".

[2] In the UK it is considered a possible carcinogen and so its use is restricted to patients who already have a diagnosis of terminal cancer.

Its British Approved Name was danthron, but it has now been changed to "dantron", the recommended International Nonproprietary Name.

[4] Dantron has the notable side-effect of causing red-colored urine.